Chamath  Palihapitiya net worth and biography

Chamath Palihapitiya Biography and Net Worth

Chamath Palihapitiya is the founder of Social Capital, an organization that makes bets on potentially transformational ideas, technology, and people. Social Capital supports entrepreneurship at all stages in diverse markets including energy transition, space, healthcare and consumer.

Prior to founding Social Capital, Chamath was an early member of Facebook's senior executive team and led the development and launch of new platforms that drove the company's global growth.

Prior to Facebook, Chamath held roles at The Mayfield Fund, AOL, and Winamp. Chamath was born in Sri Lanka, grew up in Canada, and graduated with a degree in Electrical Engineering from the University of Waterloo.

What is Chamath Palihapitiya's net worth?

The estimated net worth of Chamath Palihapitiya is at least $16.95 million as of November 17th, 2023. Mr. Palihapitiya owns 5,183,367 shares of Clover Health Investments stock worth more than $16,949,610 as of December 23rd. This net worth approximation does not reflect any other assets that Mr. Palihapitiya may own. Learn More about Chamath Palihapitiya's net worth.

How do I contact Chamath Palihapitiya?

The corporate mailing address for Mr. Palihapitiya and other Clover Health Investments executives is 317 University Ave Suite 200, Palo Alto CA, 94301. Clover Health Investments can also be reached via phone at 201-432-2133 and via email at [email protected]. Learn More on Chamath Palihapitiya's contact information.

Has Chamath Palihapitiya been buying or selling shares of Clover Health Investments?

Chamath Palihapitiya has not been actively trading shares of Clover Health Investments during the past quarter. Most recently, on Monday, November 22nd, Chamath Palihapitiya bought 1,739,130 shares of Clover Health Investments stock. The stock was acquired at an average cost of $5.75 per share, with a total value of $9,999,997.50. Learn More on Chamath Palihapitiya's trading history.

Who are Clover Health Investments' active insiders?

Clover Health Investments' insider roster includes Chelsea Clinton (Director), Vivek Garipalli (Co-Founder), and Chamath Palihapitiya (CEO). Learn More on Clover Health Investments' active insiders.

Are insiders buying or selling shares of Clover Health Investments?

During the last year, Clover Health Investments insiders bought shares 2 times. They purchased a total of 154,085 shares worth more than $116,411.60. The most recent insider tranaction occured on May, 16th when Director Anna U Loengard bought 17,085 shares worth more than $16,401.60. Insiders at Clover Health Investments own 22.3% of the company. Learn More about insider trades at Clover Health Investments.

Information on this page was last updated on 5/16/2024.

Chamath Palihapitiya Insider Trading History at Clover Health Investments

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/22/2021Buy1,739,130$5.75$9,999,997.50View SEC Filing Icon  
See Full Table

Chamath Palihapitiya Buying and Selling Activity at Clover Health Investments

This chart shows Chamath Palihapitiya's buying and selling at Clover Health Investments by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Clover Health Investments Company Overview

Clover Health Investments logo
Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat. Clover Health Investments, Corp. is based in Franklin, Tennessee.
Read More

Today's Range

Now: $3.27
Low: $3.19
High: $3.29

50 Day Range

MA: $3.58
Low: $3.00
High: $4.35

2 Week Range

Now: $3.27
Low: $0.61
High: $4.71

Volume

3,569,026 shs

Average Volume

7,722,308 shs

Market Capitalization

$1.64 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.94